<DOC>
	<DOCNO>NCT00480831</DOCNO>
	<brief_summary>This randomize , double-blind , Phase II , placebo-controlled trial add background effective treatment design evaluate efficacy , safety , pharmacokinetics PRO95780 combine paclitaxel + carboplatin + bevacizumab therapy patient previously untreated Stage IIIB , Stage IV , recurrent non-small cell lung cancer ( NSCLC ) . Approximately 120 patient randomized one two treatment arm .</brief_summary>
	<brief_title>A Study PRO95780 Patients With Previously Untreated , Advanced-Stage Non-Small Cell Lung Cancer ( APM4074g )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Ability understand willingness sign write informed consent Histologically cytologically confirm NSCLC Advanced NSCLC Measurable disease ECOG performance status 0 1 Age ≥ 18 year Use accept effective method contraception , i.e. , double barrier contraceptive method ( e.g. , diaphragm plus condom ) abstinence course study 6 month last study treatment administration woman , 1 month men Squamous cell histology Prior malignancy NSCLC ( except situ basal cell carcinoma situ cervical cancer ) , unless treat curative intent evidence disease ≥ 3 year prior randomization Untreated unstable CNS metastases Myocardial infarction unstable uncontrolled disease condition relate impacting cardiac function within 1 year prior randomization Uncontrolled hypertension History arterial thrombosis , stroke , serious hemorrhagic disorder within 1 year prior randomization Major surgical procedure within 28 day prior randomization Serious nonhealing wound ulcer , bone fracture within 21 day prior randomization Persistent history gross hemoptysis relate patient 's NSCLC Known HIV infection Known positive hepatitis C hepatitis B surface antigen Chronic daily treatment aspirin nonsteroidal antiinflammatory agent know inhibit platelet function Use anticoagulation therapy Participation clinical trial undergo investigational procedure within 30 day prior randomization Pregnancy ( e.g. , positive HCG test ) breast feed Known sensitivity product administer study Any disorder compromise ability patient provide write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>APM4074g</keyword>
</DOC>